☰

Mimi D. Michaelson, Ph.D. - Publications

Affiliations: 
2002 Harvard University, Cambridge, MA, United States 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4218-27. PMID 24965748 DOI: 10.1158/1078-0432.CCR-14-0356  0.312
2014 Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 12: 317-24. PMID 24806399 DOI: 10.1016/j.clgc.2014.03.005  0.39
2014 Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. Journal of Oncology Practice / American Society of Clinical Oncology. 10: 107-12. PMID 24399853 DOI: 10.1200/JOP.2013.000902  0.366
2014 Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 76-82. PMID 24323035 DOI: 10.1200/Jco.2012.48.5268  0.316
2014 Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Bju International. 114: E25-31. PMID 24298897 DOI: 10.1111/bju.12589  0.43
2013 Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1364-72. PMID 24225970  0.363
2013 Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3088-94. PMID 23553848 DOI: 10.1158/1078-0432.Ccr-13-0319  0.354
2012 Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1670-5. PMID 22984218 DOI: 10.2967/jnumed.112.105007  0.363
2012 Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3071-6. PMID 22851571 DOI: 10.1200/JCO.2012.42.8466  0.341
2012 Saylor PJ, Michaelson MD. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? The Oncologist. 17: 288-90. PMID 22267850 DOI: 10.1634/theoncologist.2011-0433  0.374
2008 Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. Ca: a Cancer Journal For Clinicians. 58: 196-213. PMID 18502900 DOI: 10.3322/CA.2008.0002  0.367
2006 Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 107: 530-5. PMID 16804927 DOI: 10.1002/cncr.22043  0.32
2004 Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2705-8. PMID 15102674 DOI: 10.1158/1078-0432.CCR-03-0735  0.389
2003 Michaelson MD, Smith MR, Talcott JA. Prostate cancer (metastatic). Clinical Evidence. 1012-22. PMID 15555135  0.425
2003 Michaelson MD, Smith MR. The role of bisphosphonates in the management of metastatic prostate cancer. Current Oncology Reports. 5: 245-9. PMID 12667423 DOI: 10.1007/S11912-003-0117-4  0.398
2002 Michaelson MD, Talcott JA, Smith MR. Prostate cancer: metastatic. Clinical Evidence. 881-90. PMID 12603918  0.425
Show low-probability matches.